BNP Paribas Financial Markets Increases Stock Holdings in argenx SE (NASDAQ:ARGX)

BNP Paribas Financial Markets raised its position in argenx SE (NASDAQ:ARGX - Free Report) by 138.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,232 shares of the company's stock after purchasing an additional 5,940 shares during the quarter. BNP Paribas Financial Markets' holdings in argenx were worth $6,293,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. grew its stake in shares of argenx by 21.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 34,955 shares of the company's stock valued at $21,497,000 after buying an additional 6,161 shares in the last quarter. Park Avenue Securities LLC grew its position in argenx by 40.0% in the 4th quarter. Park Avenue Securities LLC now owns 1,695 shares of the company's stock valued at $1,042,000 after acquiring an additional 484 shares in the last quarter. Ritholtz Wealth Management increased its stake in argenx by 85.5% during the fourth quarter. Ritholtz Wealth Management now owns 898 shares of the company's stock worth $552,000 after purchasing an additional 414 shares during the period. Aaron Wealth Advisors LLC lifted its position in shares of argenx by 10.1% during the fourth quarter. Aaron Wealth Advisors LLC now owns 489 shares of the company's stock worth $301,000 after purchasing an additional 45 shares in the last quarter. Finally, Ballentine Partners LLC boosted its stake in shares of argenx by 21.5% in the fourth quarter. Ballentine Partners LLC now owns 536 shares of the company's stock valued at $330,000 after purchasing an additional 95 shares during the period. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenx Price Performance

Shares of ARGX stock traded up $3.88 during trading hours on Friday, hitting $565.63. The stock had a trading volume of 433,461 shares, compared to its average volume of 323,392. The firm has a market capitalization of $34.54 billion, a PE ratio of -642.76 and a beta of 0.57. The stock's 50 day moving average is $591.92 and its 200 day moving average is $612.84. argenx SE has a twelve month low of $356.38 and a twelve month high of $678.21.

argenx (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $2.58 earnings per share for the quarter, topping analysts' consensus estimates of $2.32 by $0.26. The firm had revenue of $1.35 billion during the quarter, compared to analysts' expectations of $748.34 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. As a group, equities analysts predict that argenx SE will post 3.13 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. JMP Securities set a $699.00 price target on argenx in a report on Wednesday. Sanford C. Bernstein upgraded shares of argenx from a "market perform" rating to an "outperform" rating in a research note on Monday, March 17th. Oppenheimer lifted their price target on shares of argenx from $704.00 to $708.00 and gave the stock an "outperform" rating in a research note on Friday, May 9th. HC Wainwright reiterated a "buy" rating and set a $720.00 price target on shares of argenx in a report on Tuesday, April 8th. Finally, William Blair restated an "outperform" rating on shares of argenx in a report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, twenty have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $698.11.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.